CCP1 Inhibits Pulmonary Fibrosis by Suppressing Fibrotic Progression Through the EIF4B/PI3K/AKT Pathways
Cell Biology International · 2025
DOI: 10.1002/cbin.70051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology International, 2025. Verfasst von Qiang Ren und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases, Pulmonary Fibrosis. Die Arbeit nennt 55 Literaturangaben. Gefördert von: This study was supported by Fund of Scientific Research Innovation of the First Affiliated Hospital of Harbin Medical University (2024M34)..
Abstract (Originalsprache)
Pulmonary fibrosis (PF), particularly idiopathic pulmonary fibrosis, is a chronic and fatal disease. However, the precise pathogenic mechanisms underlying this condition remain elusive. We employed LASSO regression and random forest analyses, combined with expression profiling in TGFβ1‐induced MRC‐5 cells and bleomycin‐induced PF mouse models, to identify differentially expressed genes. These analyses revealed that cytoplasmic carboxypeptidase 1 (CCP1) was significantly downregulated in fibrotic conditions. Relevant signaling pathways were further identified through RNA sequencing (RNA‐seq). Subsequent functional studies were conducted using qRT‐PCR, western blot, hematoxylin and eosin (HE) staining, Masson's trichrome staining, immunohistochemistry (IHC), immunofluorescence, scratch assays, EdU assays, RNA interference, and co‐immunoprecipitation (co‐IP). Functional studies revealed that CCP1 knockdown promoted cell migration, proliferation, and the transformation of MRC‐5 cells into a fibrotic phenotype, as evidenced by increased expression of fibrosis‐associated markers (FN1, COL 1α1, and ACTA2) and dysregulated expression of apoptosis‐related markers (BCL2 and BAX). Conversely, CCP1 overexpression inhibited these processes. CCP1 was discovered to inhibit the PI3K/AKT signaling pathway by binding to eukaryotic initiation factor 4B (EIF4B). Overexpression of EIF4B activated the fibrotic process and interacted with c‐Myc. In vivo studies further demonstrated that CCP1 inhibited PF by suppressing EIF4B to inhibit the PI3K/AKT signaling pathway. In summary, our results demonstrate that CCP1 inhibits the development of PF by suppressing the EIF4B/PI3K/AKT axis. This study offers new perspectives into the pathogenesis of PF and underscores CCP1 as a potential therapeutic target for managing this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
- Department of Vascular Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
ORCID-Profile: Xiaomin Liu
Förderung
- This study was supported by Fund of Scientific Research Innovation of the First Affiliated Hospital of Harbin Medical University (2024M34).
Zitieren
APA
Ren, Q., Pan, Y., Tian, Z., Jiao, G., & Liu, X. (2025). CCP1 Inhibits Pulmonary Fibrosis by Suppressing Fibrotic Progression Through the EIF4B/PI3K/AKT Pathways. Cell Biology International. https://doi.org/10.1002/cbin.70051
Vancouver
Ren Q, Pan Y, Tian Z, Jiao G, Liu X. CCP1 Inhibits Pulmonary Fibrosis by Suppressing Fibrotic Progression Through the EIF4B/PI3K/AKT Pathways. Cell Biology International. 2025. doi:10.1002/cbin.70051
BibTeX
@article{Ren2025,
author = {Ren, Qiang and Pan, Yifei and Tian, Zhennan and Jiao, Guiwei and Liu, Xiaomin},
title = {CCP1 Inhibits Pulmonary Fibrosis by Suppressing Fibrotic Progression Through the EIF4B/PI3K/AKT Pathways},
journal = {Cell Biology International},
year = {2025},
doi = {10.1002/cbin.70051}
}
EUVIMED